Form 4: CVRx Director Martha Shadan Granted 19,554 Stock Options

CVRx, Inc. Director Martha Shadan reported the acquisition of 19,554 stock options with an exercise price of $6.76, vesting by June 2026.

Summary

• Martha Shadan, a Director of CVRx, Inc. (CVRX), acquired 19,554 stock options.
• The transaction date for the option grant was June 3, 2025.
• Each stock option has an exercise price of $6.76.
• The options are for Common Stock, with 19,554 shares underlying the options.
• The options will vest on the earlier of June 3, 2026, or the Issuer's 2026 annual meeting of stockholders.
• The expiration date for these stock options is June 3, 2035.
• Following this transaction, Martha Shadan beneficially owns 19,554 derivative securities directly.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally viewed positively as it aligns management's interests with shareholders and signals confidence in the company's future, though it is a routine compensation event rather than a major operational announcement.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• An insider acquiring equity, even through a grant, can be perceived as a signal of confidence in the company's future prospects.

Risks

• The value of the stock options is dependent on the future market price of CVRx, Inc. common stock exceeding the exercise price of $6.76.
• If the company's stock price does not perform well, the options may expire worthless.

Future Outlook

The stock options granted to Director Martha Shadan are forward-looking, with vesting contingent on future dates (June 3, 2026, or the 2026 annual meeting) and an expiration date ten years from the grant, indicating a long-term incentive structure.

Industry Context

The grant of stock options is a common practice in the medical device and biotechnology industries, including for directors, as a form of long-term incentive compensation designed to align the interests of leadership with shareholder value creation.

Comparison to Industry Standards

• Equity compensation, such as stock option grants, is a standard component of director remuneration across publicly traded companies, particularly in growth-oriented sectors like medical technology.
• The vesting schedule (one year from grant or next annual meeting) and ten-year expiration period are typical for director option grants, comparable to practices at companies like Medtronic or Boston Scientific for similar roles, aiming to retain talent and incentivize long-term performance.

Corporate Governance

Related Party Transactions

• The grant of stock options to Martha Shadan, a director of CVRx, Inc., constitutes a related party transaction as it involves compensation provided to an insider.

Stakeholder Impact

• Shareholders: The grant of options aims to align the director's incentives with shareholder interests, potentially leading to better long-term performance.
• Management/Directors: Martha Shadan receives equity-based compensation, which ties her personal wealth to the company's stock performance.

Next Steps

• The stock options will vest on the earlier of June 3, 2026, or the Issuer's 2026 annual meeting of stockholders.
• Following vesting, Martha Shadan will have the right to exercise these options to acquire common stock at the specified exercise price until June 3, 2035.

Key Dates

Keywords

CVRx, CVRX, Martha Shadan, Stock Options, Director, Insider Transaction, Form 4, Equity Compensation, Beneficial Ownership